NBIX
NASDAQ HealthcareNeurocrine Biosciences, Inc. - Common Stock
Drug Manufacturers - Specialty & Generic
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
๐ Market Data
| Price | $131.78 |
|---|---|
| Volume | 672,551 |
| Market Cap | 13.25B |
| Beta | 0.350 |
| RSI (14-Day) | 61.1 |
| 200-Day MA | $137.33 |
| 50-Day MA | $130.25 |
| 52-Week High | $160.18 |
| 52-Week Low | $107.96 |
| P/E Ratio | 28.22 |
| Forward P/E | 9.97 |
| Price / Book | 4.05 |
๐ฏ Investment Strategy Scores
NBIX scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Institutional Whale (77/100) โ this strategy Large-cap, institutional-quality stocks.
Lowest fit among scored strategies: ๐ Moon Shot (18/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find NBIX in your text
Paste any article, transcript, or post โ the tool will extract NBIX and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.